{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T22:29:09Z","timestamp":1784845749682,"version":"3.55.0"},"reference-count":46,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_hmbci-2021-0044_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>PCOS is the most common endocrinological disorder amongst women of reproductive age. The consequences of PCOS extend beyond the reproductive axis and may lead to the development of metabolic syndrome leading to a high risk for hypertension and cardiovascular disease. Therefore, a more comprehensive evaluation of biochemical markers that reflect the cardiovascular risk is required for further understanding of pathophysiologic mechanisms, diagnosis and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2021-0044_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this case-control study, women diagnosed with PCOS (n=100) in the age group (18\u201335 years) years were taken as cases and age matched healthy controls (n=100) were enrolled. Estimations of fasting plasma Glucose, serum total cholesterol (TC), triglycerides (TG) and High-density lipoprotein (HDL) concentrations were assayed while Low-density lipoprotein (LDL) was calculated by using Fredrickson Friedwald\u2019s formula. Serum Lipoprotein-a (Lp-a) was estimated using ELISA (Enzyme Linked Immunosorbent Assay). The quantitative data were expressed as Mean\u00a0\u00b1\u00a0Standard Deviation (SD). Unpaired Student\u2019s t-test was used to compare the values (PCOS\n                      <jats:italic>vs<\/jats:italic>\n                      Controls) and Pearson\u2019s correlation coefficient was used to elucidate the relationship between the variables.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2021-0044_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>FBS and all lipid parameters were significantly increased in PCOS patients compared to control subjects. On the other hand, HDL-C was significantly decreased as compared to the control subjects. The hormones TSH, LH, FSH, PRL and LH\/FSH ratio were significantly increased in PCOS patients compared to control subjects. Lipoprotein-a and PAI-1 was significantly increased in PCOS patients compared to the control subjects. Upon bivariate correlation analysis, Lp(a) had significant correlations with PAI-1 (r=0.35, p=0.000), WHR (r=0.25, p=0.000), LDL (r=0.52, p=0.000) and TSH (r=0.24, p=0.000). While the correlations with FBS (r=\u22120.008, p=0.91) and LH\/FSH ratio (r=\u22120.004, p=0.95) were statistically insignificant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2021-0044_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The evaluation of serum biomarkers such as Lp-a, PAI-1 and lipid profile routinely in PCOS patients may have diagnostic role in the early detection of metabolic abnormalities and endocrine derangements and timely management of comorbid Diabetes and Cardiovascular disease in PCOS females.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/hmbci-2021-0044","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T14:53:00Z","timestamp":1650379980000},"page":"357-361","source":"Crossref","is-referenced-by-count":4,"title":["A study on lipoprotein-a and PAI-1 in women with polycystic ovary syndrome"],"prefix":"10.1515","volume":"43","author":[{"given":"Ashok Kumar","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Biochemistry , Adesh Medical College and Hospital , Shahbad (M) , Haryana , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birendra Kumar","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Biochemistry , Banas Medical College and Research Institute , Palanpur , Gujrat , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9310-1219","authenticated-orcid":false,"given":"Arpita","family":"Suri","sequence":"additional","affiliation":[{"name":"Department of Biochemistry , SGT Medical College, Hospital and Research Institute , Gurgaon , Haryana , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrendra Kumar","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Koshi Hospital , Biratnagar , Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"2025121207201152982_j_hmbci-2021-0044_ref_001","unstructured":"Hoffman, BL, Schorge, JO, Halvorson, LM, Bradshaw, KD, Cunningham, FG. Polycystic ovarian syndrome and hyperandrogenism: Williams gynecology, 2nd ed New York City, USA: McGraw Hill Medical; 2012:460 p."},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_002","doi-asserted-by":"crossref","unstructured":"Gazvani, MR, Hamilton, M, Kingsland, CR, Templeton, A. Polycystic ovarian disease: a misleading label? Lancet 2000;355:411\u20132.","DOI":"10.1016\/S0140-6736(05)74039-3"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_003","doi-asserted-by":"crossref","unstructured":"Ferriman, D, Gallwey, JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440\u20137.","DOI":"10.1210\/jcem-21-11-1440"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_004","doi-asserted-by":"crossref","unstructured":"Vgontzas, AN, Legro, RS, Bixler, EO, Grayev, A, Kales, A, Chrousos, GP. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001;86:517\u201320.","DOI":"10.1210\/jc.86.2.517"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_005","doi-asserted-by":"crossref","unstructured":"Fogel, RB, Malhotra, A, Pillar, G, Pittman, SD, Dunaif, A, White, DP. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:1175\u201380.","DOI":"10.1210\/jc.86.3.1175"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_006","doi-asserted-by":"crossref","unstructured":"Rocco, A, Falaschi, P, Perrone, G, Pancheri, P, Rosa, M, Zichella, L. Psychoneuroendocrine aspects of polycystic ovary syndrome. J\u00a0Psychosom Obstet Gynecol 1991;12:169\u201379.","DOI":"10.3109\/01674829109077999"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_007","doi-asserted-by":"crossref","unstructured":"Laggari, V, Diareme, S, Christogiorgos, S, Deligeoroglou, E, Christopoulos, P, Tsiantis, J, et al.. Anxiety and depression in adolescents with polycystic ovary syndrome and Mayer-Rokitansky-K\u00fcster-Hauser syndrome. J Psychosom Obstet Gynecol 2009;30:83\u20138.","DOI":"10.1080\/01674820802546204"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_008","doi-asserted-by":"crossref","unstructured":"Franks, S. Polycystic ovary syndrome. N Engl J Med 1995;333:853\u201361.","DOI":"10.1056\/NEJM199509283331307"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_009","doi-asserted-by":"crossref","unstructured":"Azziz, R, Woods, KS, Reyna, R, Key, TJ, Knochenhauer, ES. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745\u20139.","DOI":"10.1210\/jc.2003-032046"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_010","doi-asserted-by":"crossref","unstructured":"Gill, H, Tiwari, P, Dabadghao, P. Prevalence of polycystic ovary syndrome in young women from North India: a community-based study. Indian J Endocrinol Metab 2012;16:S389\u201392.","DOI":"10.4103\/2230-8210.104104"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_011","doi-asserted-by":"crossref","unstructured":"Spandana, JC, Shetty, PK. A study on the clinical, biochemical and hormonal profile of polycystic ovary syndrome patients attending tertiary care hospital. Int J Reprod Contracept Obstet and Gynecol 2017;6:1986\u201392.","DOI":"10.18203\/2320-1770.ijrcog20171963"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_012","doi-asserted-by":"crossref","unstructured":"Balen, A. Pathogenesis of polycystic ovary syndrome\u2013the enigma unravels? Lancet 1999;354:966\u20137.","DOI":"10.1016\/S0140-6736(99)00218-4"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_013","doi-asserted-by":"crossref","unstructured":"Legro, RS, Kunselman, AR, Dunaiff, A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111:607\u201313.","DOI":"10.1016\/S0002-9343(01)00948-2"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_014","doi-asserted-by":"crossref","unstructured":"Essah, PA, Nestler, JE. Metabolic syndrome in women with polycystic ovary syndrome. Fertil Steril 2006;86:S18.","DOI":"10.1016\/j.fertnstert.2006.04.013"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_015","doi-asserted-by":"crossref","unstructured":"Essah, PA, Nestler, JE. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest 2006;29:270\u201380.","DOI":"10.1007\/BF03345554"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_016","doi-asserted-by":"crossref","unstructured":"Kalra, A, Nair, S, Rai, L. Association of obesity and insulin resistance with dyslipidemia in Indian women with polycystic ovarian syndrome. Indian J Med Sci 2006;60:447\u201353.","DOI":"10.4103\/0019-5359.27971"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_017","doi-asserted-by":"crossref","unstructured":"Diamanti-Kandarakis, E. Role of obesity and adiposity in polycystic ovary syndrome. Int J Obes 2007;31:S8\u201313.","DOI":"10.1038\/sj.ijo.0803730"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_018","doi-asserted-by":"crossref","unstructured":"Diamanti-Kandarakis, E, Papavassiliou, AG, Kandarakis, SA, Chrousos, GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metabol 2007;18:280\u20135.","DOI":"10.1016\/j.tem.2007.07.004"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_019","doi-asserted-by":"crossref","unstructured":"Farrell, K, Antoni, MH. Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions. Fertil Steril 2010;94:1565\u201374.","DOI":"10.1016\/j.fertnstert.2010.03.081"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_020","doi-asserted-by":"crossref","unstructured":"Magnotti, M, Futterweit, W. Obesity and the polycystic ovary syndrome. Med Clin 2007;91:1151\u201368.","DOI":"10.1016\/j.mcna.2007.06.010"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_021","doi-asserted-by":"crossref","unstructured":"Pinon, P, Kaski, JC. Inflammation, atherosclerosis, and cardiovascular disease risk: PAPP-A, Lp-PLA2, and cystatin C. New insights or redundant information? Rev Esp Cardiol 2006;59:247\u201358.","DOI":"10.1016\/S1885-5857(06)70028-7"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_022","doi-asserted-by":"crossref","unstructured":"Scicchitano, P, Dentamaro, I, Carbonara, R, Bulzis, G, Dachille, A, Caputo, P, et al.. Cardiovascular risk in women with PCOS. Int J Endocrinol Metab 2012;10:611\u20138.","DOI":"10.5812\/ijem.4020"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_023","doi-asserted-by":"crossref","unstructured":"Lippi, G, Guddi, G. Lipoprotein (a): from ancestral benefit to modern pathogen? Q J Med 2000;93:75\u201384.","DOI":"10.1093\/qjmed\/93.2.75"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_024","doi-asserted-by":"crossref","unstructured":"Sur, D, Chakravorty, R. Association of coronary heart disease risk and lipid profile in Indian women with polycystic ovary syndrome. J Clin Gynecol Obstet 2016;5:23\u20136.","DOI":"10.14740\/jcgo375w"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_025","doi-asserted-by":"crossref","unstructured":"Kelly, CJ, Lyall, H, Petrie, JR, Gould, GW, Connell, JM, Rumley, A, et al.. A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome. J Clin Endocrinol Metabol 2002;87:3287\u201390.","DOI":"10.1210\/jcem.87.7.8634"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_026","doi-asserted-by":"crossref","unstructured":"Carmassi, F, De Negri, F, Fioriti, R, De Giorgi, A, Giannarelli, C, Fruzzetti, F, et al.. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. Thromb Res 2005;116:207\u201314.","DOI":"10.1016\/j.thromres.2004.11.026"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_027","doi-asserted-by":"crossref","unstructured":"Wood, JR, Nelson, VL, Ho, C, Jansen, E, Wang, CY, Urbanek, M, et al.. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J Biol Chem 2003;278:26380\u201390.","DOI":"10.1074\/jbc.M300688200"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_028","doi-asserted-by":"crossref","unstructured":"Diamanti-Kandarakis, E, Piperi, C, Argyrakopoulou, G, Spina, J, Papanastasiou, L, Bergiele, A, et al.. Polycystic ovary syndrome: the influence of environmental and genetic factors. Hormones-Athens 2006;5:17.","DOI":"10.14310\/horm.2002.11165"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_029","doi-asserted-by":"crossref","unstructured":"Rabelo-Acevedo, M, Ram\u00edrez-Vick, M. Association between the polycystic ovary syndrome and the metabolic syndrome in Puerto Rico. Puert Rico Health Sci J 2005;24:203\u20136.","DOI":"10.1016\/S1530-891X(20)43640-7"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_030","doi-asserted-by":"crossref","unstructured":"Wang, ET, Calderon-Margalit, R, Cedars, MI, Daviglus, ML, Merkin, SS, Schreiner, PJ, et al.. Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia. Obstet Gynecol 2011;117:6\u201313.","DOI":"10.1097\/AOG.0b013e31820209bb"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_031","unstructured":"Cho, LW, Randeva, HS, Atkin, SL. Cardiometabolic aspects of polycystic ovarian syndrome. Vasc Health Risk Manag 2007;3:55."},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_032","doi-asserted-by":"crossref","unstructured":"Cussons, AJ, Stuckey, BG, Watts, GF. Metabolic syndrome and cardiometabolic risk in PCOS. Curr Diabetes Rep 2007;7:66\u201373.","DOI":"10.1007\/s11892-007-0012-8"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_033","doi-asserted-by":"crossref","unstructured":"Hoffman, LK, Ehrmann, DA. Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metabol 2008;4:215\u201322.","DOI":"10.1038\/ncpendmet0755"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_034","doi-asserted-by":"crossref","unstructured":"Westerveld, HE, Hoogendoorn, M, de Jong, AW, Goverde, AJ, Fauser, BC, Dallinga-Thie, GM. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. Pharmacol Therapeut 2008;119:223\u201341.","DOI":"10.1016\/j.pharmthera.2008.04.009"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_035","doi-asserted-by":"crossref","unstructured":"Rocha, MP, Marcondes, JA, Barcellos, CR, Hayashida, SA, Curi, DD, da Fonseca, AM, et al.. Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors. Gynecol Endocrinol 2011;27:814\u20139.","DOI":"10.3109\/09513590.2010.508852"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_036","doi-asserted-by":"crossref","unstructured":"Naidu, JN, Swapna, GN, Kumar, AN, Krishnamma, M, Anitha, M. Importance of elevated insulin resistance, dyslipidemia and status of antioxidant vitamins in polycystic ovary disease. Free Radic Antioxidants 2013;3:17\u20139.","DOI":"10.1016\/j.fra.2013.03.001"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_037","doi-asserted-by":"crossref","unstructured":"Banu, LM, Wahab, MA, Debnath, BC, Begum, D, Arslan, MI. Characteristics of insulin and androgen status in polycystic ovary syndrome. Bangladesh J Med Biochem 2010;3:11\u20135.","DOI":"10.3329\/bjmb.v3i1.13801"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_038","doi-asserted-by":"crossref","unstructured":"Yilmaz, M, Biri, A, Bukan, N, Karako\u00e7, A, Sancak, B, T\u00f6r\u00fcner, F, et al.. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005;20:258\u201363.","DOI":"10.1080\/09513590400027265"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_039","doi-asserted-by":"crossref","unstructured":"Tsouma, I, Kouskouni, E, Demeridou, S, Boutsikou, M, Hassiakos, D, Chasiakou, A, et al.. Correlation of visfatin levels and lipoprotein lipid profiles in women with polycystic ovary syndrome undergoing ovarian stimulation. Gynecol Endocrinol 2014;30:516\u20139.","DOI":"10.3109\/09513590.2014.896896"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_040","doi-asserted-by":"crossref","unstructured":"G\u00fcd\u00fcc\u00fc, N, \u0130\u015f\u00e7i, H, Yi\u011fiter, AB, D\u00fcnder, \u0130. C-reactive protein and lipoprotein-a as markers of coronary heart disease in polycystic ovary syndrome. J Turk Ger Gynecol Assoc 2012;13:227.","DOI":"10.5152\/jtgga.2012.35"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_041","doi-asserted-by":"crossref","unstructured":"Lindholm, A, Bixo, M, Eliasson, M, Hudecova, M, Arnadottir, R, Holte, J, et al.. Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome. Gynecol Endocrinol 2010;26:743\u20138.","DOI":"10.3109\/09513590.2010.487592"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_042","doi-asserted-by":"crossref","unstructured":"Orio, FJr., Palomba, S, Cascella, T, Tauchmanov, L, Nardo, LG, Di Biase, S, et al.. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reprod Biomed Online 2004;9:505\u201310.","DOI":"10.1016\/S1472-6483(10)61634-3"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_043","doi-asserted-by":"crossref","unstructured":"Tarkun, I, Canturk, Z, Arslan, BC, Turemen, E, Tarkun, P. The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocr J 2004;51:467\u201372.","DOI":"10.1507\/endocrj.51.467"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_044","doi-asserted-by":"crossref","unstructured":"Oral, B, Mermi, B, Dilek, M, Alano\u011flu, G, S\u00fct\u00e7\u00fc, R. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:110\u20136.","DOI":"10.1080\/09513590802549874"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_045","doi-asserted-by":"crossref","unstructured":"Elci, E, Kaya, C, Cim, N, Yildizhan, R, Elci, GG. Evaluation of cardiac risk marker levels in obese and non-obese patients with polycystic ovaries. Gynecol Endocrinol 2017;33:43\u20137.","DOI":"10.1080\/09513590.2016.1203893"},{"key":"2025121207201152982_j_hmbci-2021-0044_ref_046","doi-asserted-by":"crossref","unstructured":"Sahay, S, Jain, M, Dash, D, Choubey, L, Jain, S, Singh, TB. Role of plasminogen activator inhibitor type 1 (PAI-1) in PCOS patient. Int J Reprod Contracept Obstet Gynecol 2017;6:4052\u20138.","DOI":"10.18203\/2320-1770.ijrcog20174061"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2021-0044\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2021-0044\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:11:52Z","timestamp":1765527112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2021-0044\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,4,20]]},"published-print":{"date-parts":[[2022,9,28]]}},"alternative-id":["10.1515\/hmbci-2021-0044"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2021-0044","relation":{},"ISSN":["1868-1891"],"issn-type":[{"value":"1868-1891","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]}}}